In contrast to dabrafenib, another BRAF inhibitor vemurafenib, which also suppresses proliferation of BRAF-mutated melanoma cells, does not suppress RIP3 activity, indicating that these kinase inhibitors act similarly, but their effect on cancer cells may differ depending on cellular context. Here, RIPK3 is linked to cancer.